- Home
- HLVX vs ASMB Comparison
HLVX vs ASMB Comparison
Compare HLVX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ASMB
- Stock Information
- Founded
- HLVX 2020
- ASMB 2005
- Country
- HLVX United States
- ASMB United States
- Employees
- HLVX N/A
- ASMB N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- ASMB Health Care
- Exchange
- HLVX Nasdaq
- ASMB Nasdaq
- Market Cap
- HLVX 83.7M
- ASMB 73.6M
- IPO Year
- HLVX 2022
- ASMB 2010
- Fundamental
- Price
- HLVX $1.86
- ASMB $10.42
- Analyst Decision
- HLVX Hold
- ASMB Strong Buy
- Analyst Count
- HLVX 5
- ASMB 3
- Target Price
- HLVX $2.33
- ASMB $33.00
- AVG Volume (30 Days)
- HLVX 287.5K
- ASMB 28.3K
- Earning Date
- HLVX 05-08-2025
- ASMB 05-07-2025
- Dividend Yield
- HLVX N/A
- ASMB N/A
- EPS Growth
- HLVX N/A
- ASMB N/A
- EPS
- HLVX N/A
- ASMB N/A
- Revenue
- HLVX N/A
- ASMB $28,520,000.00
- Revenue This Year
- HLVX N/A
- ASMB $10.82
- Revenue Next Year
- HLVX N/A
- ASMB N/A
- P/E Ratio
- HLVX N/A
- ASMB N/A
- Revenue Growth
- HLVX N/A
- ASMB 298.16
- 52 Week Low
- HLVX $1.34
- ASMB $7.75
- 52 Week High
- HLVX $16.31
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- HLVX 66.30
- ASMB 53.40
- Support Level
- HLVX $1.64
- ASMB $9.82
- Resistance Level
- HLVX $1.75
- ASMB $10.78
- Average True Range (ATR)
- HLVX 0.11
- ASMB 0.83
- MACD
- HLVX 0.04
- ASMB 0.24
- Stochastic Oscillator
- HLVX 100.00
- ASMB 88.12
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.